777 Shares in Chemed Corporation $CHE Acquired by Savant Capital LLC

Savant Capital LLC purchased a new stake in shares of Chemed Corporation (NYSE:CHE) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 777 shares of the company’s stock, valued at approximately $378,000.

Several other institutional investors also recently bought and sold shares of CHE. SVB Wealth LLC purchased a new position in shares of Chemed in the 1st quarter valued at $30,000. WPG Advisers LLC purchased a new stake in Chemed during the 1st quarter worth $32,000. Creekmur Asset Management LLC acquired a new stake in Chemed in the 2nd quarter valued at $28,000. Geneos Wealth Management Inc. raised its position in Chemed by 330.4% in the first quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock valued at $61,000 after purchasing an additional 76 shares during the period. Finally, Zions Bancorporation National Association UT purchased a new position in Chemed in the first quarter valued at about $68,000. 95.85% of the stock is currently owned by hedge funds and other institutional investors.

Chemed Stock Performance

CHE opened at $435.18 on Monday. The company has a market capitalization of $6.16 billion, a P/E ratio of 23.01, a PEG ratio of 2.69 and a beta of 0.43. The company has a 50-day moving average of $443.97 and a 200-day moving average of $482.84. Chemed Corporation has a 1-year low of $408.42 and a 1-year high of $623.60.

Chemed (NYSE:CHE) last posted its quarterly earnings results on Tuesday, October 28th. The company reported $5.27 EPS for the quarter, missing analysts’ consensus estimates of $5.39 by ($0.12). Chemed had a return on equity of 25.89% and a net margin of 11.02%.The firm had revenue of $624.90 million during the quarter, compared to analyst estimates of $626.04 million. During the same quarter last year, the business posted $5.64 earnings per share. The firm’s revenue for the quarter was up 3.1% on a year-over-year basis. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. As a group, sell-side analysts expect that Chemed Corporation will post 21.43 earnings per share for the current fiscal year.

Chemed Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Monday, November 17th will be paid a dividend of $0.60 per share. The ex-dividend date is Monday, November 17th. This represents a $2.40 annualized dividend and a yield of 0.6%. Chemed’s dividend payout ratio (DPR) is 12.69%.

Insiders Place Their Bets

In other Chemed news, Director Patrick P. Grace sold 150 shares of the business’s stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $463.39, for a total transaction of $69,508.50. Following the completion of the sale, the director owned 3,397 shares in the company, valued at $1,574,135.83. The trade was a 4.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Kevin J. Mcnamara sold 3,000 shares of the firm’s stock in a transaction dated Friday, September 26th. The stock was sold at an average price of $461.28, for a total transaction of $1,383,840.00. Following the completion of the transaction, the chief executive officer owned 96,197 shares in the company, valued at approximately $44,373,752.16. The trade was a 3.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 3.29% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on CHE. Bank of America decreased their target price on Chemed from $610.00 to $595.00 and set a “buy” rating for the company in a research report on Wednesday, September 10th. Oppenheimer decreased their price target on Chemed from $650.00 to $580.00 and set an “outperform” rating for the company in a report on Thursday, July 31st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Chemed in a research report on Wednesday, October 8th. Zacks Research raised shares of Chemed from a “strong sell” rating to a “hold” rating in a research report on Thursday, October 30th. Finally, Jefferies Financial Group upgraded shares of Chemed from a “hold” rating to a “buy” rating and upped their target price for the company from $490.00 to $550.00 in a research note on Tuesday, September 2nd. Four analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $574.25.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.